CTNNA1
CTNNA1 encodes catenin alpha 1 (α-catenin), a protein associated with catenin signaling.
CTNNA1 encodes catenin alpha 1 (α-catenin), a protein associated with catenin signaling. Recent research has examined CTNNA1 in the context of a germline mutation occurring with synchronous follicular and papillary thyroid carcinomas and numerous adenomatoid nodules; however, the relationship between CTNNA1 mutation and thyroid neoplasia remains poorly understood.
The broader literature places CTNNA1 within a disease-relevant catenin-signaling context that includes the Wnt/β-catenin pathway. Studies of related β-catenin signaling have investigated effects on tumor biology, including METTL14/Wnt9a-mediated cancer stem-cell activity, TCF/LEF-dependent transcription, and potential combinations with radiation therapy, immunotherapy, or anti-PD-1 therapy. Other work has linked modulation of this pathway to rheumatoid arthritis-associated bone erosion, diabetic osteoporosis and osteoblast ferroptosis, intestinal inflammatory signaling involving Toll-like receptor 4 and NF-κB, and immune-cell function in glioblastoma. These findings support continued investigation of CTNNA1 and catenin-network alterations in cancer, inflammation, and skeletal disease, while not establishing CTNNA1 itself as a validated therapeutic target.
Where the papers sit
9 papers from the last 6 months study CTNNA1 directly · updated from PubMed 14 Nov 2026
Study type 0 clinical trials · 1 observational · 2 human data · 6 preclinical
Themes one subject · 1 new direction
Those 9 are all about one subject.
-
Catenin Biology
Catenin-centered work links alpha-catenin and β-catenin to epithelial integrity, Wnt signaling, cancer, inflammation and tissue remodeling. Proteomic and proximity-mapping studies are expanding the known interaction and ubiquitination networks. Pharmacological approaches target Wnt/β-catenin activity or use it to improve radiotherapy, immunotherapy and anti-inflammatory treatment. The field remains mechanistically broad, with no single therapeutic direction established.
Germline CTNNA1 is presented as a susceptibility factor for a distinctive spectrum of synchronous thyroid lesions
The case of synchronous minimally invasive follicular thyroid carcinoma, papillary thyroid carcinoma, and diffuse adenomatoid nodules in a woman with a pathogenic germline CTNNA1 mutation 42823177Oct assigns CTNNA1 an inherited disease-susceptibility role rather than the β-catenin pathway, therapeutic-target, or tissue-remodeling roles described elsewhere in the set. It expands CTNNA1-associated disease to a distinctive combination of thyroid neoplasia and proliferative lesions, while the absence of a PTEN alteration supports the mutation as the notable genetic finding in this case.
Papers
The 9 papers from the last 6 months that study CTNNA1 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Catenin Biology (9)
- Integrated Proteomic and Ubiquitinomic Reveal Ubiquitination Remodeling in Pelvic Organ Prolapse. Journal of proteome research · 6 Nov 2026 PMID 42992879
- Alpha-catenin Mutation-associated Synchronous Follicular Thyroid Carcinoma and Papillary Thyroid Carcinoma With Numerous Adenomatoid Nodules. Anticancer research · 1 Oct 2026 PMID 42823177
- Quercetin ameliorates rheumatoid arthritis-associated bone erosion via inhibiting the Wnt3a/β-catenin signaling axis. Molecular biology reports · 15 Sept 2026 PMID 42742793
- Harnessing (-)-epigallocatechin-3-gallate (EGCG) with chitosan-coated liposomes to modulate the radiation effect in cancer cells through alteration in the miR-139-5p-β-catenin axis. Biomaterials science · 15 Sept 2026 PMID 42741861
- Comprehensive proximity proteomics expand the known interactome of the oncoprotein β-catenin. Scientific reports · 2 Sept 2026 PMID 42680804
- All-trans retinoic acid suppresses CD8+ T-cell terminal exhaustion and potentiates anti-PD-1 therapy in glioblastoma. Signal transduction and targeted therapy · 25 Aug 2026 PMID 42642387
- Design and development of 2,7-disubstituted 6-methoxyquinazolin-4 (3H)-ones as potential anti-cancer agents possibly through downregulation of Wnt/β-catenin/TCF4 signaling pathway. Future medicinal chemistry · 17 Aug 2026 PMID 42605575
- Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer. European journal of pharmacology · 6 Aug 2026 PMID 42562044
- Overexpression of CD97 in intestinal epithelial cells attenuates LPS-induced pro-inflammatory cytokine induction via stabilization of β-catenin early in life. PloS one · 30 Jul 2026 PMID 42531273
By study type
Observational studies and case reports (1)
- Alpha-catenin Mutation-associated Synchronous Follicular Thyroid Carcinoma and Papillary Thyroid Carcinoma With Numerous Adenomatoid Nodules. Anticancer research · 1 Oct 2026 PMID 42823177
Human data, design not indexed (2)
- Integrated Proteomic and Ubiquitinomic Reveal Ubiquitination Remodeling in Pelvic Organ Prolapse. Journal of proteome research · 6 Nov 2026 PMID 42992879
- Comprehensive proximity proteomics expand the known interactome of the oncoprotein β-catenin. Scientific reports · 2 Sept 2026 PMID 42680804
Preclinical: animal, cell and lab studies (6)
- Quercetin ameliorates rheumatoid arthritis-associated bone erosion via inhibiting the Wnt3a/β-catenin signaling axis. Molecular biology reports · 15 Sept 2026 PMID 42742793
- Harnessing (-)-epigallocatechin-3-gallate (EGCG) with chitosan-coated liposomes to modulate the radiation effect in cancer cells through alteration in the miR-139-5p-β-catenin axis. Biomaterials science · 15 Sept 2026 PMID 42741861
- All-trans retinoic acid suppresses CD8+ T-cell terminal exhaustion and potentiates anti-PD-1 therapy in glioblastoma. Signal transduction and targeted therapy · 25 Aug 2026 PMID 42642387
- Design and development of 2,7-disubstituted 6-methoxyquinazolin-4 (3H)-ones as potential anti-cancer agents possibly through downregulation of Wnt/β-catenin/TCF4 signaling pathway. Future medicinal chemistry · 17 Aug 2026 PMID 42605575
- Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer. European journal of pharmacology · 6 Aug 2026 PMID 42562044
- Overexpression of CD97 in intestinal epithelial cells attenuates LPS-induced pro-inflammatory cytokine induction via stabilization of β-catenin early in life. PloS one · 30 Jul 2026 PMID 42531273
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-10-27. Drafted by language models from published abstracts; not medical advice.